BNF:

Endocrine

Status:

Do Not Prescribe (DNP), Grey, Green

Decision Date:

None

Comments

Prescribe by brand

Humalog (Insulin Lispro) 

GREEN: 100units/ml - Preferred cost-effective brand (Decision date March 2026)

GREY: 200units/ml* (decision date - October 2017)

Admelog (Insulin Lispro biosimilar)

GREEN: 100units/ml - Due to be discontinued June 2026, do not initiate new patients (decision date - June 2023)

Lyumjev (Insulin Lispro)

GREEN: 100units/ml 

GREY: 200units/ml* (Decision date - October 2020) 

Lispro Sanofi (Insulin Lispro biosimilar)

DO NOT PRESCRIBE (DNP): 100units/ml. (Decision based on lack of clarity between biosimilar and originator name and the risk of inadvertent switching)  (Decision date - September 2018)

*See MHRA April 2015, High strength, fixed combination and biosimilar insulin products to minimise the risk of medication error. 

search again